Pfizer's obesity strategy runs through the $4.9 billion Metsera acquisition completed in late 2025, which brought a deep pipeline of next-generation peptide candidates in obesity and cardiometabolic disease. The lead asset, berobenatide (MET-097i, also known as PF'3944), is an ultra-long-acting GLP-1 receptor agonist that posted 14.1% mean placebo-subtracted weight loss in the Phase 2b VESPER-1 study and 15.9% weight loss with no plateau at 32 weeks in the VESPER-1 exploratory extension presented at ADA 2026 on June 6.
The Phase 3 program runs to 10+ trials. VESPER-4 (weekly dosing, obesity without T2D) initiated late 2025; VESPER-5 (weekly, obesity + T2D) launched March 2026; VESPER-6 (monthly maintenance) is planned. MET-233i is a monthly amylin analog in earlier-stage development, intended for combination with berobenatide. Pfizer also retained the rights to discontinued danuglipron (the small-molecule oral GLP-1 dropped in April 2025 after a drug-induced liver injury case) and is developing PF-08653944 in earlier development.
Leadership transitioned on June 18, 2026 when Pfizer announced CFO Dave Denton's departure on August 15 for a consumer-goods opportunity, with Cecile Guegan (SVP, Finance, Global Biopharmaceutical Business since 2022) named Interim CFO effective August 16 while an external search runs. Pfizer reaffirmed 2026 guidance the same day: revenues of $59.5-62.5B and adjusted diluted EPS of $2.80-3.00.
Outside obesity, Pfizer's peptide footprint includes ASCO 2026 oncology presentations across 40+ company-sponsored, investigator-sponsored, and collaborative abstracts — including peptide-drug conjugate programs. Stories here cover trial readouts, manufacturing decisions, leadership transitions, and the broader oncology footprint. See [[metsera]], [[vesper-1]], and [[asco-2026]].
ASCO 2026 abstracts will release on asco.org/abstracts beginning 5:00 PM ET on Wednesday May 21, ahead of the May 29-June 2 Chicago meeting. The peptide-oncology slate is substantial: Pfizer announced 40+ company-sponsored, investigator-sponsored, and collaborative oncology abstracts including three late-breaking sessions; Bicycle Therapeutics has an oral and four poster presentations on zelenectide pevedotin (BT8009, nectin-4 PDC) with Duravelo-2 interim data; Avacta has Phase Ia/Ib data on AVA6000 (FAP-Dox PDC) in salivary gland cancers; BioVaxys's MVP-S survivin peptide vaccine PESCO trial data; BriaCell's six Bria-IMT/Bria-OTS+ presentations on metastatic breast cancer; and Replimune's RP1 + nivolumab 3-year melanoma OS data. Crinetics CRN09682 SSTR2 NDC BRAVESST2 update expected.
Pfizer reported April 29 Q1 2026 revenue of $14.45 billion (vs. $13.92B consensus) and adjusted diluted EPS of $0.75 (vs. $0.72), with non-COVID operational revenue up 7%. The company reaffirmed 2026 guidance of $59.5–62.5B in revenue and $2.80–3.00 in adjusted EPS. On the obesity portfolio, Pfizer confirmed 20+ planned and ongoing studies across the diverse obesity pipeline acquired with Metsera, including 10 Phase 3 trials of PF'3944 (MET-097i) — the recently initiated Phase 3 VESPER-4 once-weekly study, the planned VESPER-5 in T2D, the planned VESPER-6 once-monthly maintenance study, and at least seven more. MET-233i, a monthly amylin analog, is in Phase 1 monotherapy and combination-with-PF'3944 development.
Pfizer announced that data from more than 40 company-sponsored, investigator-sponsored, and collaborative research abstracts will appear at ASCO 2026 in Chicago (May 29–June 2). The slate spans Pfizer's diverse oncology pipeline including peptide-drug conjugate programs, bispecific T-cell engagers, and antibody-drug conjugates. Combined with previously announced ASCO 2026 acceptances from Bicycle Therapeutics, BriaCell, Greenwich LifeSciences, BioVaxys, and Immutep, the meeting is shaping up as the most peptide-and-immuno-conjugate-heavy ASCO in recent memory — building on the foundation laid at AACR 2026 in San Diego.